Jonathan Levy

Dr. Jonathan Levy

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2017 in European Journal of Neurology
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
DBD. Bensmail
D. Bensmail
ABA. Brotier‐Chomienne
A. Brotier‐Chomienne
SBS. Butel
S. Butel
CJC. Joussain
C. Joussain
HPH. Prigent
H. Prigent

23 August 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
JLJonathan Levy
Jonathan Levy
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
JLJean-Yves Loze
Jean-Yves Loze
DBDjamel Bensmail
Djamel Bensmail
Background: Current guidelines recommend intramuscular botulinum toxin type A (BoNT-A) injection as first-line treatment for spasticity, a frequent and impairing feature of various central nervous system (CNS) lesions such as stroke. Patients with spasticity commonly require BoNT-A injections once every 3 to 4 months. We conducted a nationwide, population-based, retrospective cohort study, using the French National Hospital Discharge Database (PMSI), to describe BoNT-A use for spasticity in clinical practice in France between 2014 and 2020. The PMSI database covers the whole French population, corresponding to over 66 million persons.Methods: We first searched the PMSI database for healthcare facility discharge of patients who received BoNT-A injections between 2014 and 2020, corresponding to the first set. For each BoNT-A-treated patient, we identified the medical condition for which BoNT-A may have been indicated. Another search of the PMSI database focused on patients admitted for acute stroke between 2014 and 2016 and their spasticity-related care pathway (second set). Overall, two subpopulations were analysed: 138,481 patients who received BoNT-A injections between 2014 and 2020, and 318,025 patients who survived a stroke event between 2014 and 2016 and were followed up until 2020.Results: Among the 138,481 BoNT-A-treated patients, 53.5% received only one or two BoNT-A injections. Most of these patients (N = 85,900; 62.0%) received BoNT-A because they had CNS lesions. The number of patients with CNS lesions who received ≥1 BoNT-A injection increased by a mean of 7.5% per year from 2014 to 2019, but decreased by 0.2% between 2019 and 2020, corresponding to the COVID-19 outbreak. In stroke survivors (N = 318,025), 10.7% were coded with post-stroke spasticity, 2.3% received ≥1 BoNT-A injection between 2014 and 2020, and only 0.8% received ≥3 injections within the 12 months following BoNT-A treatment initiation, i.e., once every 3 to 4 months.Conclusion: Our analysis of the exhaustive PMSI database showed a suboptimal implementation of BoNT-A treatment recommendations in France. BoNT-A treatment initiation and re-administration are low, particularly in patients with post-stroke spasticity. Further investigations may help explain this observation, and may target specific actions to improve spasticity-related care pathway.

1 January 2018 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
HPH. Prigent
H. Prigent
DBDjamel Bensmail
Djamel Bensmail

1 July 2019 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
FMFranco Molteni
Franco Molteni
GCGiovanni Cannaviello
Giovanni Cannaviello
TLThibaud Lansaman
Thibaud Lansaman
NRNicolas Roche
Nicolas Roche
DBDjamel Bensmail
Djamel Bensmail

1 July 2020 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
ALAntoine Léotard
Antoine Léotard
CLChristine Lawrence
Christine Lawrence
JPJulie Paquereau
Julie Paquereau
DBDjamel Bensmail
Djamel Bensmail
HPHélène Prigent
Hélène Prigent

12 April 2023 in Toxins
Verified
Journal Article
Open access
PDF file
DBDjamel Bensmail
Djamel Bensmail
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
JLJean-Yves Loze
Jean-Yves Loze
JLJonathan Levy
Jonathan Levy
There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d’Information, PMSI) covering the entire French population. Among 105,206 patients coded with MS, we identified those who received ≥1 BoNT-A injection, administered within striated muscle for MS-related spasticity and/or within the detrusor smooth muscle for neurogenic detrusor overactivity (NDO). A total of 8427 patients (8.0%) received BoNT-A injections for spasticity, 52.9% of whom received ≥3 BoNT-A injections with 61.9% of the repeated injections administered every 3 to 6 months. A total of 2912 patients (2.8%) received BoNT-A injections for NDO, with a mean of 4.7 injections per patient. Most repeated BoNT-A injections within the detrusor smooth muscle (60.0%) were administered every 5 to 8 months. There were 585 patients (0.6%) who received both BoNT-A injections within striated muscle and the detrusor smooth muscle. Overall, our study highlights a broad range of BoNT-A treatment practices between 2014 and 2020 in patients with MS.